Free Trial

Tenet Healthcare (THC) Stock Forecast & Price Target

$156.57
-0.17 (-0.11%)
(As of 04:29 PM ET)

Tenet Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
16

Based on 17 Wall Street analysts who have issued ratings for Tenet Healthcare in the last 12 months, the stock has a consensus rating of "Buy." Out of the 17 analysts, 1 has given a hold rating, 14 have given a buy rating, and 2 have given a strong buy rating for THC.

Consensus Price Target

$152.69
-2.43% Downside
According to the 17 analysts' twelve-month price targets for Tenet Healthcare, the average price target is $152.69. The highest price target for THC is $197.00, while the lowest price target for THC is $85.00. The average price target represents a forecasted downside of -2.43% from the current price of $156.57.
Get the Latest News and Ratings for THC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Tenet Healthcare and its competitors.

Sign Up

THC Analyst Ratings Over Time

TypeCurrent Forecast
10/5/23 to 10/4/24
1 Month Ago
9/5/23 to 9/4/24
3 Months Ago
7/7/23 to 7/6/24
1 Year Ago
10/5/22 to 10/5/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
13 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$152.69$152.69$121.18$84.18
Forecasted Upside-2.43% Downside-5.78% Downside-8.06% Downside38.65% Upside
Consensus Rating
Buy
Buy
Buy
Buy

THC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

THC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Tenet Healthcare Stock vs. The Competition

TypeTenet HealthcareMedical CompaniesS&P 500
Consensus Rating Score
3.06
2.78
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside-2.61% Downside850.33% Upside7.73% Upside
News Sentiment Rating
Positive News

See Recent THC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/1/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$168.00 ➝ $168.00+2.71%
8/14/2024UBS Group
4 of 5 stars
 Boost TargetBuy ➝ Buy$180.00 ➝ $197.00+27.91%
7/30/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetBuy ➝ Buy$156.00 ➝ $173.00+13.09%
7/30/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$145.00 ➝ $175.00+14.53%
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$156.00 ➝ $171.00+11.11%
7/25/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$130.00 ➝ $175.00+17.04%
7/25/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$139.00 ➝ $171.00+14.37%
7/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$155.00 ➝ $170.00+13.71%
6/28/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$150.00 ➝ $155.00+16.40%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$107.00 ➝ $140.00+4.67%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$153.00+16.31%
5/1/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$109.00 ➝ $136.00+16.51%
5/1/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$118.00 ➝ $130.00+13.23%
5/1/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$95.00 ➝ $122.00+8.64%
3/27/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$122.00+19.21%
11/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $85.00+45.40%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$92.00 ➝ $98.00+27.60%
12/6/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$40.00 ➝ $45.00+2.25%
10/25/2022Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Whit Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$89.00 ➝ $55.00+40.99%
10/21/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$79.00 ➝ $64.00+71.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:49 PM ET.


THC Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Tenet Healthcare is $152.69, with a high forecast of $197.00 and a low forecast of $85.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenet Healthcare in the last twelve months. There is currently 1 hold rating, 14 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THC shares.

According to analysts, Tenet Healthcare's stock has a predicted downside of -2.48% based on their 12-month stock forecasts.

Tenet Healthcare has been rated by research analysts at Barclays, Cantor Fitzgerald, Citigroup, Raymond James, The Goldman Sachs Group, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Tenet Healthcare more than other "medical" companies. The consensus rating for Tenet Healthcare is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how THC compares to other companies.


This page (NYSE:THC) was last updated on 10/4/2024 by MarketBeat.com Staff
From Our Partners